IN2014DN06118A - - Google Patents

Info

Publication number
IN2014DN06118A
IN2014DN06118A IN6118DEN2014A IN2014DN06118A IN 2014DN06118 A IN2014DN06118 A IN 2014DN06118A IN 6118DEN2014 A IN6118DEN2014 A IN 6118DEN2014A IN 2014DN06118 A IN2014DN06118 A IN 2014DN06118A
Authority
IN
India
Prior art keywords
oncogenic viral
immune response
polypeptide
polypeptides
subject
Prior art date
Application number
Other languages
English (en)
Inventor
John H Lee
Daniel W Vermeer
Original Assignee
Sanford Res Usd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Res Usd filed Critical Sanford Res Usd
Publication of IN2014DN06118A publication Critical patent/IN2014DN06118A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IN6118DEN2014 2012-01-24 2013-01-23 IN2014DN06118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261590089P 2012-01-24 2012-01-24
PCT/US2013/022696 WO2013112549A1 (en) 2012-01-24 2013-01-23 Polynucleotides for treating oncogenic viral polypeptide positive tumors

Publications (1)

Publication Number Publication Date
IN2014DN06118A true IN2014DN06118A (es) 2015-08-14

Family

ID=48873849

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6118DEN2014 IN2014DN06118A (es) 2012-01-24 2013-01-23

Country Status (10)

Country Link
US (3) US9492526B2 (es)
EP (2) EP3269387B1 (es)
JP (2) JP6219849B2 (es)
KR (1) KR102195196B1 (es)
CN (2) CN110042110A (es)
DK (1) DK2806889T3 (es)
ES (1) ES2646590T3 (es)
HK (1) HK1203833A1 (es)
IN (1) IN2014DN06118A (es)
WO (1) WO2013112549A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
EP3371316B1 (en) 2015-11-04 2022-10-19 Hookipa Biotech GmbH Vaccines against hepatitis b virus
LT3373959T (lt) 2015-11-12 2022-07-25 Hookipa Biotech Gmbh Arenavirusų dalelės, kaip vėžio vakcinos
GB201605210D0 (en) 2016-03-29 2016-05-11 Oxford Immunotec Ltd Assay
KR20190033483A (ko) * 2016-06-03 2019-03-29 이투빅스 코포레이션 인간 파필로마바이러스 (hpv)-연관 질환의 치료를 위한 조성물 및 방법
CN106655327A (zh) * 2016-10-18 2017-05-10 云南中烟工业有限责任公司 一种压缩式充电装置
US11197063B2 (en) 2016-11-11 2021-12-07 Google Llc Methods, systems, and media for modifying the presentation of video content on a user device based on a consumption of the user device
US20210024586A1 (en) * 2018-03-06 2021-01-28 Precigen, Inc. Human papillomavirus vaccines and uses of the same
EP4159746A1 (en) * 2020-05-25 2023-04-05 Genematrix Inc. Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO1999061608A2 (en) 1998-05-26 1999-12-02 Institute Of Molecular And Cell Biology Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
WO2004030636A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
EP2162544B1 (en) 2007-05-15 2013-04-17 Transgene SA Vectors for multiple gene expression
AU2010246273B2 (en) * 2009-04-28 2014-04-03 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途

Also Published As

Publication number Publication date
KR102195196B1 (ko) 2020-12-28
US20160376324A1 (en) 2016-12-29
DK2806889T3 (da) 2017-11-20
EP2806889B1 (en) 2017-08-16
CN110042110A (zh) 2019-07-23
EP3269387B1 (en) 2019-07-17
US9492526B2 (en) 2016-11-15
EP2806889A1 (en) 2014-12-03
CN104159607A (zh) 2014-11-19
WO2013112549A1 (en) 2013-08-01
ES2646590T3 (es) 2017-12-14
HK1203833A1 (en) 2015-11-06
EP2806889A4 (en) 2016-04-20
JP6219849B2 (ja) 2017-10-25
JP2018038405A (ja) 2018-03-15
US9969779B2 (en) 2018-05-15
US20150023996A1 (en) 2015-01-22
JP6655051B2 (ja) 2020-02-26
EP3269387A1 (en) 2018-01-17
US20180237477A1 (en) 2018-08-23
JP2015506179A (ja) 2015-03-02
KR20140131929A (ko) 2014-11-14

Similar Documents

Publication Publication Date Title
IN2014DN06118A (es)
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
IN2014KN02929A (es)
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
MX2015007575A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
NZ627078A (en) Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
EP2576791A4 (en) METHOD AND COMPOSITIONS WITH LISTERIA FOR THE HELP TREATMENT OF CANCER
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
IN2015DN02546A (es)
IL220092A (en) 44cd monoclonal antibody for use in the treatment of squamous cell carcinoma of the head and neck
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
UA110024C2 (uk) Вакцинний вектор і спосіб посилення імунної відповіді
WO2014004385A3 (en) Anti-cancer vaccines
MX2019003961A (es) Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
MX347805B (es) Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.
EP2940133A4 (en) VACCINE AGAINST HPV AND / OR HEPATITIS B INFECTION CONTAINING CHIMERIC HPV / HBS PROTEIN AS AN ACTIVE INGREDIENT
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
PT2859092T (pt) ¿vacina terapêutica para tratamento de diabetes tipo 1 em crianças, aplicação do separador de células e método de multiplicação de células treg para produzir a vacina terapêutica para tratamento de diabetes tipo 1¿
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
MX2012012489A (es) Preparacion de polipeptidos y sales de los mismos.